PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v6i4.4091ArticleA Correlation Analysis of Postoperative Hypercoagulability and Peripheral Circulating Tumor Cells in Patients with Lung Cancerhttps://artdesignp.com/journal/PAR/6/4/10.26689/par.v6i4.4091ZhangXuguang,ZhangDuo,LiHefei2022642022-07-28Objective: To explore the correlation between peripheral circulating tumor cells and hypercoagulability in patients with lung cancer after surgery. Methods: From January 2017 to December 2021, 89 patients with lung cancer who were treated in the Affiliated Hospital of Hebei University were selected as the research subjects, and a retrospective analysis was conducted to analyze and observe the D-dimer (DD), fibrinogen (FIB), and platelet (PLT) levels in peripheral blood, as well as detect peripheral CTC. Results: There were statistical differences in TMN staging, tumor metastasis, and lymph node metastasis in the clinical data, but there were no statistical differences in gender, smoking history, and pathological classification. After retrospective analysis and comparison of the patients, the DD (mg/ml), FIB (g/L), and PLT (×109/L) levels of the CTC positive group were 3.41 ± 0.58, 3.98 ± 0.87, and 367.26 ± 34.98, respectively; the CTC negative group’s DD (mg/ml), FIB (g/L), and PLT (×109/L) levels were 0.89 ± 0.49, 1.06 ± 0.45, and 234.69 ± 35.69, respectively, and the differences were statistically significant. The factors affecting the prognosis of patients included TMN staging and CTC; the number of CTC positives in the death group was significantly higher than that in the survival group, and there was a statistical difference between the groups. Gender, age, smoking history, pathological type, and surgical resection had no effect on the prognosis of patients. Among the enrolled patients, the survival rate was 71.91%. Conclusion: CTC-positive patients have a higher probability of hypercoagulability after surgery and are prone to tumor metastasis; thus, CTC can be used as a judgment index for the prognosis of patients.

Wang H, Zhou Z, Shen D, et al., 2021, The Relationship Between Peripheral Blood Circulating Tumor Cells and Coagulation Indexes in Patients with Non-Small Cell Lung Cancer After Surgery. China Cancer Clinic and Rehabilitation, 28(03): 335–337.

Mai C, Tang H, Lin L, 2021, Analysis of the Detection Results of Peripheral Blood Circulating Tumor Cells in Patients with Lung Cancer. Internal Medicine, 16(01): 92–94.

Mei J, 2021, Strict Study on the Levels of Circulating Tumor Cells and NSE, CEA and CYFRA21-1 in Patients with Lung Cancer. Marker Immunoassay and Clinic, 28(01): 37–40.

Sun J, 2020, Correlation Between Peripheral Blood Circulating Tumor Cell Expression and Keratin 19 Fragment and Fibrinogen in Patients with Lung Cancer. China Health Engineering, 19(01): 88–89.

Lin S, Hao Y, Lv Y, et al., 2019, Clinical Correlation of Peripheral Blood Circulating Tumor Cells and Their Chemokine Receptor CCR9 with Non-Small Cell Lung Cancer. Journal of Postgraduate Medicine, 32(09): 948–953.

Nie Q, Liu H, Lu Y, 2019, Study on EP Regimen Regulated by the Mechanism of Epithelial-Mesenchymal Transition of Peripheral Blood Circulating Tumor Cells in the Treatment of Small Cell Lung Cancer. Chongqing Medicine, 48(01): 91–93.

Xiao P, Mei J, Li R, et al., 2018, The Value of Peripheral Blood Circulating Tumor Cells in Different Stages and Different Types of Lung Cancer. Cancer Progress, 16(06): 763–765.

Hu R, Wu Z, 2018, Correlation Between Peripheral Blood Circulating Tumor Cells and Clinical Staging of Patients with Non-Small Cell Lung Cancer. Journal of Changjiang University (Self-Science Edition), 15(08): 29–31.

Tong B, 2018, Expression and Analysis of PD-L1 in the Primary Tumor of Non-Small Cell Lung Cancer and Circulating Tumor Cells in Peripheral Blood. Peking Union Medical College.

Lou D, 2018, The Clinical Significance of Peripheral Blood Circulating Tumor Cell Count in Lung Cancer Patients. Dalian Medical University.

Ye C, Chen L, Wang J, et al., 2017, Effects of Pemetrexed Combined with Cisplatin on EGFR Expression and Prognosis in Peripheral Blood Circulating Tumor Cells in Patients with Advanced Non-Small Cell Lung Cancer. China Medical Frontiers (Electronic Edition), 9(12): 34–37.

Chen Z, Hu H, Chen B, 2017, Relationship Between Peripheral Blood Circulating Tumor Cells and Clinicopathological Factors and Prognosis of Non-Small Cell Lung Cancer. Journal of Practical Medicine, 33(23): 3894–3898.

Zhu J, Zhou L, Zhou D, et al., 2017, Expression of Circulating Tumor Cells in Peripheral Blood of Lung Cancer Patients and Their Relationship with Serum CY-FRA21-1 and FG Levels. China Cancer Clinic and Rehabilitation, 24(05): 541–544.

Jiang B, Jin C, Tu C, et al., 2016, Influence of EGFR Expression in Peripheral Blood Circulating Tumor Cells on TKI Treatment Effect and Prognosis in Patients with Advanced Non-Small Cell Lung Cancer. Shandong Medicine, 56(40): 86–88 + 115.

Wan J, Shen H, Huang H, et al., 2015, A Preliminary Study on the Relationship Between Peripheral Blood Circulating Tumor Cells and Clinical Characteristics in Patients with Non-Small Cell Lung Cancer. Journal of Clinical and Pathology, 35(01): 43–47.

Bai L, Xie J, Bai L, et al., 2021, Detection of Circulating Tumor Cells in Peripheral Blood of NSCLC and Its Relationship with TNM Staging and Prognosis. Modern Oncology, 29(19): 3380–3385.

Li W, Li Y, Liang W, et al., 2021, Differences in the Content of Circulating Tumor Cells in Peripheral Arterial Blood and Venous Blood of Patients with Lung Cancer and Its Clinical Significance. Journal of Clinical Pulmonology, 26(04): 567–569 + 574.

Sun J, 2020, The Correlation Between the Expression of Circulating Tumor Cells in Peripheral Blood of Lung Cancer Patients and the Keratin 19 Fragment and Fibrinogen. China Health Engineering, 19(01): 88–89.

He X, Li S, Ma R, et al., 2019, The Relationship Between Blood Hypercoagulability and Peripheral Blood Circulating Tumor Cells After Lung Cancer Surgery. China Medical Frontiers, 11(11): 115–119.

Li C, Yang Y, Yan D, 2016, Clinical Application Value of Peripheral Venous Circulating Tumor Cell Count in Patients with Non-Small Cell Lung Cancer. China Primary Medicine, 23(12): 1768–1771.